Functional characterization of pro-biotic pharmaceuticals by quantitative analysis of gene expression

Arzneimittel-Forschung/Drug Research

Volumn 53, Issue 5, 2003, Pages 385-391

  Giese, Thomas ^a   Zimmermann, Kurt ^b   Meuer, Stefan C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SymbioPharm GmbH   (Germany)

Author keywords

Enterococcus faecalis; Escherichia coli; Pro biotics, gene expression, quality control, real time polymerase chain reaction; Pro Symbioflor ; Symbioflor 2; Symbiofor 1

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2ALPHA; PRO SYMBIOFLOR; PROBIOTIC AGENT; SYMBIOFLOR 1; SYMBIOFLOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MONITORING; DRUG STABILITY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GENE EXPRESSION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; STANDARDIZATION; TEMPERATURE SENSITIVITY;

EID: 0038627512     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297125     Document Type: Article

References (14)

1. Isolauri, E., Sutas, Y., Kankaanpaa, P. et al., Probiotics: effects on immunity. Am. J. Clin. Nutr. 73 (Suppl.), 444 S (2001)
2. Shanahan, F., Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm. Bowel Dis. 6, 107 (2000)
3. Shanahan, F., Shanahan, F., Probiotics and inflammatory bowel disease: from fads and fantasy to facts and future. Br. J. Nutr. 88 (Suppl. 1), 5 (2002)
4. Thorpe, R., Wadhwa, M., Mire-Sluis, A., The use of bioassays for the characterisation and control of biological therapeutic products produced by biotechnology. Dev. Biol. Stand. 91, 79 (1997)
5. Jeffcoate, S., The role of bioassays in the development, licensing and batch control of biotherapeutics. Trends Biotechnol. 14, 121 (1996)
6. Giese T., Development of Quantitative RT-PCR Tests for the Expression of Cytokine Genes on the Light Cycler, in: Rapid Cycle Real-Time PCR: Methods and Applications, S. Meuer, C. Witwer, K. Nakagawara (eds.), pp. 251-261, Springer Verlag, Berlin - Heidelberg etc. (2001)
7. Rosenkranz, W., Grundmann, E., Immunomodulator action of living, nonpathogenic Enterococcus faecalis bacteria from humans. Arzneim.-Forsch./Drug Res. 44 (II), 691 (1994)
8. Hornung, V., Rothenfusser, S., Britsch, S. et al., Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168, 4531 (2002)
9. Alexander, C., Rietschel, E. T., Bacterial lipopolysaccharides and innate immunity. J. Endotoxin Res. 7, 167 (2001)
10. Husband, A. J., Novel vaccination strategies for the control of mucosal infection. Vaccine 11, 107 (1993)
11. Heeg, K., Sparwasser, T., Lipford, G. B. et al., Bacterial DNA as an evolutionary conserved ligand signalling danger of infection to immune cells. Eur. J. Clin. Microbiol. Infect. Dis. 17, 464 (1998)
12. Krieg, A. M., Immune effects and mechanisms of action of CpG motifs. Vaccine 19, 618 (2000)
13. Weese, J. S., Microbiologic evaluation of commercial probiotics. J. Am. Vet. Med. Assoc. 15, 794 (2002)
14. Tuomola, E., Crittenden, R., Playne, M. et al., Quality assurance criteria for probiotic bacteria. Am. J. Clin. Nutr. 73 (Suppl.), 393S (2001)